Literature DB >> 16985970

A Primary Care Physician's Perspective on Benign Prostatic Hyperplasia.

Louis Kuritzky.   

Abstract

Primary care clinicians are generally the first point of contact for men who suffer troublesome symptoms of benign prostatic hyperplasia. Although a subset of these patients will ultimately require referral to a urologist for an invasive procedure to provide symptom control, the majority can be appropriately managed in the ambulatory setting. Most symptomatic men respond favorably to alpha-blockers, which provide prompt improvement in symptoms such as nocturia. Although alpha-blockers may control troublesome lower urinary tract symptoms, there is no suggestion that they forestall the need for surgery or reduce the likelihood of development of acute urinary retention. Therefore, clinicians need to become familiar with use of 5-alpha-reductase inhibitors, as this is the only class of pharmacotherapy that has been shown to have a diseasemodifying effect.

Entities:  

Year:  2003        PMID: 16985970      PMCID: PMC1502361     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  10 in total

1.  Screening for prostate cancer: recommendations and rationale.

Authors: 
Journal:  Am Fam Physician       Date:  2003-02-15       Impact factor: 3.292

2.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

Review 3.  Benign prostatic hyperplasia.

Authors:  L Kuritzky
Journal:  Compr Ther       Date:  1998-03

4.  Protracted cholestatic hepatitis after the use of prostata.

Authors:  S Hamid; S Rojter; J Vierling
Journal:  Ann Intern Med       Date:  1997-07-15       Impact factor: 25.391

5.  Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia.

Authors:  G Bartsch; H R Müller; M Oberholzer; H P Rohr
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

6.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

7.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

Review 8.  Benign prostatic hyperplasia: use of drug therapy in primary care.

Authors:  R Beduschi; M C Beduschi; J E Oesterling
Journal:  Geriatrics       Date:  1998-03

9.  The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists.

Authors:  M J Barry; F J Fowler; L Bin; J C Pitts; C J Harris; A G Mulley
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

10.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Authors:  H Lepor; W O Williford; M J Barry; M K Brawer; C M Dixon; G Gormley; C Haakenson; M Machi; P Narayan; R J Padley
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

  10 in total
  2 in total

1.  Role of Primary Care Clinicians in the Diagnosis and Treatment of LUTS and BPH.

Authors:  Louis Kuritzky
Journal:  Rev Urol       Date:  2004

Review 2.  Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ?

Authors:  Martin M Miner
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.